Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases: Clinical impact

Toni Ibrahim, Alberto Farolfi, Emanuela Scarpi, Laura Mercatali, Laura Medri, Marianna Ricci, Oriana Nanni, Luigi Serra, Dino Amadori

Research output: Contribution to journalArticle

Abstract

Objective: As hormone receptor and human epidermal growth factor receptor-2 (HER-2) expression in primary breast tumors frequently differs from that of paired metastases, we first evaluated the discordance rate (DR) of estrogen receptor (ER), progesterone receptor (PgR), HER-2, and Ki67 in breast cancer patients and then assessed the discordance effect on prognosis. Methods: Of 145 cases reviewed, 120 with samples available from both primary tumors and paired metastases were included in the study. For each receptor, the DR was calculated as the proportion of discordant cases with respect to the total number of patients. Results: A change in ER status was observed in 19 cases (DR 16.4%), while PgR status was modified in 48 cases (DR 41.7%). HER-2 was altered in 21 cases (DR 17.5%), and Ki67 in 33 patients (DR 38.8%). Patients with Ki67

Original languageEnglish
Pages (from-to)150-157
Number of pages8
JournalOncology
Volume84
Issue number3
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Progesterone Receptors
Estrogen Receptors
Hormones
human ERBB2 protein
Neoplasms

Keywords

  • Advanced breast cancer prognosis
  • Discordance
  • Hormone receptors
  • Human epidermal growth factor receptor-2
  • Ki67
  • Metastasis biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases : Clinical impact. / Ibrahim, Toni; Farolfi, Alberto; Scarpi, Emanuela; Mercatali, Laura; Medri, Laura; Ricci, Marianna; Nanni, Oriana; Serra, Luigi; Amadori, Dino.

In: Oncology, Vol. 84, No. 3, 01.2013, p. 150-157.

Research output: Contribution to journalArticle

@article{0fd9628a2e8348c18bf2a3b14e2ba473,
title = "Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases: Clinical impact",
abstract = "Objective: As hormone receptor and human epidermal growth factor receptor-2 (HER-2) expression in primary breast tumors frequently differs from that of paired metastases, we first evaluated the discordance rate (DR) of estrogen receptor (ER), progesterone receptor (PgR), HER-2, and Ki67 in breast cancer patients and then assessed the discordance effect on prognosis. Methods: Of 145 cases reviewed, 120 with samples available from both primary tumors and paired metastases were included in the study. For each receptor, the DR was calculated as the proportion of discordant cases with respect to the total number of patients. Results: A change in ER status was observed in 19 cases (DR 16.4{\%}), while PgR status was modified in 48 cases (DR 41.7{\%}). HER-2 was altered in 21 cases (DR 17.5{\%}), and Ki67 in 33 patients (DR 38.8{\%}). Patients with Ki67",
keywords = "Advanced breast cancer prognosis, Discordance, Hormone receptors, Human epidermal growth factor receptor-2, Ki67, Metastasis biopsy",
author = "Toni Ibrahim and Alberto Farolfi and Emanuela Scarpi and Laura Mercatali and Laura Medri and Marianna Ricci and Oriana Nanni and Luigi Serra and Dino Amadori",
year = "2013",
month = "1",
doi = "10.1159/000345795",
language = "English",
volume = "84",
pages = "150--157",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases

T2 - Clinical impact

AU - Ibrahim, Toni

AU - Farolfi, Alberto

AU - Scarpi, Emanuela

AU - Mercatali, Laura

AU - Medri, Laura

AU - Ricci, Marianna

AU - Nanni, Oriana

AU - Serra, Luigi

AU - Amadori, Dino

PY - 2013/1

Y1 - 2013/1

N2 - Objective: As hormone receptor and human epidermal growth factor receptor-2 (HER-2) expression in primary breast tumors frequently differs from that of paired metastases, we first evaluated the discordance rate (DR) of estrogen receptor (ER), progesterone receptor (PgR), HER-2, and Ki67 in breast cancer patients and then assessed the discordance effect on prognosis. Methods: Of 145 cases reviewed, 120 with samples available from both primary tumors and paired metastases were included in the study. For each receptor, the DR was calculated as the proportion of discordant cases with respect to the total number of patients. Results: A change in ER status was observed in 19 cases (DR 16.4%), while PgR status was modified in 48 cases (DR 41.7%). HER-2 was altered in 21 cases (DR 17.5%), and Ki67 in 33 patients (DR 38.8%). Patients with Ki67

AB - Objective: As hormone receptor and human epidermal growth factor receptor-2 (HER-2) expression in primary breast tumors frequently differs from that of paired metastases, we first evaluated the discordance rate (DR) of estrogen receptor (ER), progesterone receptor (PgR), HER-2, and Ki67 in breast cancer patients and then assessed the discordance effect on prognosis. Methods: Of 145 cases reviewed, 120 with samples available from both primary tumors and paired metastases were included in the study. For each receptor, the DR was calculated as the proportion of discordant cases with respect to the total number of patients. Results: A change in ER status was observed in 19 cases (DR 16.4%), while PgR status was modified in 48 cases (DR 41.7%). HER-2 was altered in 21 cases (DR 17.5%), and Ki67 in 33 patients (DR 38.8%). Patients with Ki67

KW - Advanced breast cancer prognosis

KW - Discordance

KW - Hormone receptors

KW - Human epidermal growth factor receptor-2

KW - Ki67

KW - Metastasis biopsy

UR - http://www.scopus.com/inward/record.url?scp=84871233229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871233229&partnerID=8YFLogxK

U2 - 10.1159/000345795

DO - 10.1159/000345795

M3 - Article

C2 - 23257904

AN - SCOPUS:84871233229

VL - 84

SP - 150

EP - 157

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -